Medulloblastoma – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Medulloblastoma – Pipeline Review, H1 2020’, provides an overview of the Medulloblastoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Medulloblastoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Medulloblastoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Medulloblastoma

– The report reviews pipeline therapeutics for Medulloblastoma by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Medulloblastoma therapeutics and enlists all their major and minor projects

– The report assesses Medulloblastoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Medulloblastoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Medulloblastoma

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Medulloblastoma pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aettis Inc

Bayer AG

Biogenera SpA

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Co

CDG Therapeutics Inc

Curis Inc

Dalriada Therapeutics Inc

DelMar Pharmaceuticals Inc

Dracen Pharmaceuticals Inc

Eli Lilly and Co

Guangdong Zhongsheng Pharmaceutical Co Ltd

Immunomic Therapeutics Inc

IMPACT Therapeutics Inc

Janpix Inc

Lumos Pharma Inc

MacroGenics Inc

Mana Therapeutics Inc

Midatech Pharma Plc

MimiVax LLC

Moleculin Biotech LLC

Nascent Biotech Inc

Novartis AG

Oncoheroes Biosciences Inc

Ono Pharmaceutical Co Ltd

Oxurion NV

Pfizer Inc

Progenics Pharmaceuticals Inc

Sapience Therapeutics Inc

Senhwa Biosciences Inc

Shionogi & Co Ltd

Stemsynergy Therapeutics Inc

TheraBiologics Inc

VBI Vaccines Inc

Vyriad Inc

Y-mAbs Therapeutics Inc

Table of Contents

Table of Contents

Introduction

Medulloblastoma - Overview

Medulloblastoma - Therapeutics Development

Medulloblastoma - Therapeutics Assessment

Medulloblastoma - Companies Involved in Therapeutics Development

Medulloblastoma - Drug Profiles

Medulloblastoma - Dormant Projects

Medulloblastoma - Discontinued Products

Medulloblastoma - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Medulloblastoma, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Medulloblastoma – Pipeline by Aettis Inc, H1 2020

Medulloblastoma – Pipeline by Bayer AG, H1 2020

Medulloblastoma – Pipeline by Biogenera SpA, H1 2020

Medulloblastoma – Pipeline by Boehringer Ingelheim International GmbH, H1 2020

Medulloblastoma – Pipeline by Bristol-Myers Squibb Co, H1 2020

Medulloblastoma – Pipeline by CDG Therapeutics Inc, H1 2020

Medulloblastoma – Pipeline by Curis Inc, H1 2020

Medulloblastoma – Pipeline by Dalriada Therapeutics Inc, H1 2020

Medulloblastoma – Pipeline by DelMar Pharmaceuticals Inc, H1 2020

Medulloblastoma – Pipeline by Dracen Pharmaceuticals Inc, H1 2020

Medulloblastoma – Pipeline by Eli Lilly and Co, H1 2020

Medulloblastoma – Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, H1 2020

Medulloblastoma – Pipeline by Immunomic Therapeutics Inc, H1 2020

Medulloblastoma – Dormant Projects, H1 2020

List of Figures

List of Figures

Number of Products under Development for Medulloblastoma, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports